Stellar(US) | $2,700,000 | (Jan 9, 2025)
Aspect Biosystems | $115,000,000 | (Jan 9, 2025)
Certified by Founder
Lodge
XyloCor Therapeutics, Inc.
start up
United States
- King of Prussia, Pennsylvania
- 09/01/2025
- Series B
- $67,500,000
XyloCor Therapeutics is a development-stage, biotechnology company dedicated to developing first-in-class gene therapies for patients with unmet medical need in cardiovascular disease.
- Industry Research Services
- Website https://www.xylocor.com/
- LinkedIn https://www.linkedin.com/company/xylocor-therapeutics-inc./
Relief Cardiovascular | $12,000,000 | (Jan 9, 2025)
VitVio | $2,000,000 | (Jan 9, 2025)
Qualified Health | $30,000,000 | (Jan 9, 2025)
Evergreen Nephrology | $130,000,000 | (Jan 9, 2025)
UNLISTED | $2,250,000 | (Jan 9, 2025)
Zeto / Rapid Full-Montage EEG | $31,000,000 | (Jan 9, 2025)
Red Rover Health, Inc. | $4,000,000 | (Jan 9, 2025)
Ubiety Technologies, Inc. | $10,000,000 | (Jan 9, 2025)